Zimura phase 2b trial results positive in geographic atrophy secondary to dry AMD

Zimura, a complement factor C5 inhibitor, reduced geographic atrophy growth in a phase 2b clinical trial, according to a press release from Iveric bio.
The international, randomized, double-masked, sham-controlled, multicenter trial evaluated 286 patients with geographic atrophy secondary to dry age-related macular degeneration over 12 months.
Patients who received Zimura (avacincaptad pegol) 2 mg experienced a mean reduction in geographic atrophy growth of 27.38% at 12 months compared with the sham group (P = .0072). Those who received Zimura 4 mg had a mean reduction of 27.81% compared with

Full Story →